<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Med Sci</journal-id><journal-id journal-id-type="publisher-id">ijms</journal-id><journal-title>International Journal of Medical Sciences</journal-title><issn pub-type="epub">1449-1907</issn><publisher><publisher-name>Ivyspring International Publisher</publisher-name><publisher-loc>Sydney, Australia</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">15912203</article-id><article-id pub-id-type="pmc">1074719</article-id><article-id pub-id-type="publisher-id">ijmsv01p0116</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Paper</subject></subj-group></article-categories><title-group><article-title>A Randomized Study of Epithelial Ovarian Cancer: Is Chemotherapy Useful after Complete Remission?</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name><surname>Nicoletto</surname><given-names>M. O.</given-names></name><xref ref-type="other" rid="bio1"></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name><surname>Tumolo</surname><given-names>S.</given-names></name><xref ref-type="other" rid="bio2"></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name><surname>Falci</surname><given-names>C.</given-names></name><xref ref-type="other" rid="bio3"></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name><surname>Donach</surname><given-names>M.</given-names></name><xref ref-type="other" rid="bio4"></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name><surname>Visonà</surname><given-names>E.</given-names></name></contrib><contrib contrib-type="author" xlink:type="simple"><name><surname>Rosabian</surname><given-names>A.</given-names></name></contrib><contrib contrib-type="author" xlink:type="simple"><name><surname>Nascimben</surname><given-names>O.</given-names></name></contrib><contrib contrib-type="author" xlink:type="simple"><name><surname>Cima</surname><given-names>G.P.</given-names></name></contrib><contrib contrib-type="author" xlink:type="simple"><name><surname>Vinante</surname><given-names>O.</given-names></name></contrib><contrib contrib-type="author" xlink:type="simple"><name><surname>Azzoni</surname><given-names>P.</given-names></name></contrib><contrib contrib-type="author" xlink:type="simple"><name><surname>Fiorentino</surname><given-names>M.V.</given-names></name></contrib></contrib-group><aff> GOCCNE Group (Gruppo Oncologico Cooperativo Clinico Nord-Est ovaio), Padua, Italy</aff><author-notes><corresp><bold>Corresponding address:</bold> M. O. Nicoletto, Department of Medical Oncology, Ospedale Busonera, via Gattamelata 64, 35128 Padova, Italy. Tel: ++39 049 821-5927, fax: ++39 049 821-5928, e-mail: <email>mariaorn@libero.it</email>; <email>mariaornella.nicoletto@fastwebnet.it</email></corresp><fn fn-type="conflict"><p><bold>Conflict of interest</bold>: The authors have declared that no conflict of interest exists.</p></fn></author-notes><pub-date pub-type="collection"><year>2004</year></pub-date><pub-date pub-type="epub"><day>1</day><month>6</month><year>2004</year></pub-date><volume>1</volume><issue>2</issue><fpage>116</fpage><lpage>125</lpage><history><date date-type="received"><day>23</day><month>3</month><year>2004</year></date><date date-type="accepted"><day>17</day><month>5</month><year>2004</year></date></history><copyright-statement>© Ivyspring International Publisher. This is an open access article. Distribution or copying is permitted, provided that the article is in whole, unmodified, and properly cited.</copyright-statement><copyright-year>2004</copyright-year><abstract><p><italic><offsets xml_i="3846" xml_f="3856" txt_i="11" txt_f="21">Objective.</offsets></italic><offsets xml_i="3865" xml_f="4056" txt_i="21" txt_f="212"> The aim of this study is to verify whether consolidation chemotherapy with Cisplatin improves disease-free survival and/or overall survival in patients affected by epithelial ovarian cancer.</offsets></p><p><italic><offsets xml_i="4071" xml_f="4079" txt_i="213" txt_f="221">Methods.</offsets></italic><offsets xml_i="4088" xml_f="4583" txt_i="221" txt_f="716"> A multicenter study examined 122 randomized patients in complete remission as judged by laparoscopy or laparotomy following first-line chemotherapy consisting of ACy (Adriamycin + Cyclophosphamide), PCy (Cisplatin + Cyclophosphamide), or Mitoxantrone + Carboplatin. Sixty-one of these patients were treated with 3 cycles of 5-Fluorouracil (FU) 500 mg/m2 for 5 days followed by Cisplatin at 100 mg/m2 on the 6th or 7th day every 28 days; the other 61 received no further treatment (nihil group).</offsets></p><p><italic><offsets xml_i="4598" xml_f="4606" txt_i="717" txt_f="725">Results.</offsets></italic><offsets xml_i="4615" xml_f="5418" txt_i="725" txt_f="1528"> Sixty patients in the Cisplatin arm were evaluable. There were 36 relapses in the FU+Cisplatin arm and 30 in the nihil arm. Peritoneal relapses were 25% for Cisplatin treatment vs. 16.4 % for nihil. There were 29 deaths in the Cisplatin arm vs. 27 for nihil. Median overall survival time (95 months with Cisplatin vs. 96 months in the nihil group) and median disease-free survival (66 months with Cisplatin vs. 73 in the nihil group) were similar in both arms (p=0.66 and p=0.41, respectively). There were no significant differences in tumor stage and grade between the two arms. Seven patients presented a second neoplasm during follow-up: six in the nihil arm, but only one patient in the Cisplatin arm. Death in these patients was due to the second neoplasm and not to progression of ovarian cancer.</offsets></p><p><italic><offsets xml_i="5433" xml_f="5444" txt_i="1529" txt_f="1540">Conclusion.</offsets></italic><offsets xml_i="5453" xml_f="5626" txt_i="1540" txt_f="1713"> Three courses of additional platinum+FU treatment after five cycles of first-line chemotherapy without FU produced no increase in overall survival or disease-free survival.</offsets></p></abstract><kwd-group><kwd>Epithelial Ovarian Cancer</kwd><kwd>Consolidation Chemotherapy</kwd><kwd>Cisplatin</kwd><kwd>Fluorouracil</kwd><kwd>Absence of Residuum</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title><offsets xml_i="5868" xml_f="5883" txt_i="1721" txt_f="1736">1. Introduction</offsets></title><p><offsets xml_i="5894" xml_f="6086" txt_i="1737" txt_f="1929">Cure rates for advanced ovarian cancer are low, regardless of the type of treatment received. An average 5-year survival rate of 10% (0-15%) has been obtained with abdominal radiation therapy </offsets><xref ref-type="bibr" rid="B1"><offsets xml_i="6117" xml_f="6118" txt_i="1929" txt_f="1930">1</offsets></xref><offsets xml_i="6125" xml_f="6126" txt_i="1930" txt_f="1931">-</offsets><xref ref-type="bibr" rid="B4"><offsets xml_i="6157" xml_f="6158" txt_i="1931" txt_f="1932">4</offsets></xref><offsets xml_i="6165" xml_f="6223" txt_i="1932" txt_f="1990">, and response rates vary from 3 to 30% with chemotherapy </offsets><xref ref-type="bibr" rid="B5"><offsets xml_i="6254" xml_f="6255" txt_i="1990" txt_f="1991">5</offsets></xref><offsets xml_i="6262" xml_f="6263" txt_i="1991" txt_f="1992">-</offsets><xref ref-type="bibr" rid="B9"><offsets xml_i="6294" xml_f="6295" txt_i="1992" txt_f="1993">9</offsets></xref><offsets xml_i="6302" xml_f="6488" txt_i="1993" txt_f="2179">. Recent multivariate analyses of prognostic factors suggest that the size of the residual tumor after first surgery is the most important variable in predicting the response to therapy </offsets><xref ref-type="bibr" rid="B3"><offsets xml_i="6519" xml_f="6520" txt_i="2179" txt_f="2180">3</offsets></xref><offsets xml_i="6527" xml_f="6757" txt_i="2180" txt_f="2410">; for each 10% increase in maximum cytoreduction, survival increased by 5.5%. There was an average difference in survival of approximately 11 months between the less-than-25% and the greater-than-75% maximum cytoreduction cohorts </offsets><xref ref-type="bibr" rid="B10"><offsets xml_i="6789" xml_f="6791" txt_i="2410" txt_f="2412">10</offsets></xref><offsets xml_i="6798" xml_f="6799" txt_i="2412" txt_f="2413">.</offsets></p><p><offsets xml_i="6806" xml_f="6906" txt_i="2414" txt_f="2514">The use of Cisplatin, which presents encouraging response rates, is associated with longer survival </offsets><xref ref-type="bibr" rid="B11"><offsets xml_i="6938" xml_f="6940" txt_i="2514" txt_f="2516">11</offsets></xref><offsets xml_i="6947" xml_f="7324" txt_i="2516" txt_f="2893">; however, often the efficacy of highly aggressive regimens is only seen in those patients with highly favorable prognostic factors (optimal cytoreductive surgery). According to the Goldie-Coldman theory, early administration of aggressive regimens could selectively interfere with the number of drug-resistant cells arising by spontaneous mutation, reducing them to a minimum </offsets><xref ref-type="bibr" rid="B1"><offsets xml_i="7355" xml_f="7356" txt_i="2893" txt_f="2894">1</offsets></xref><offsets xml_i="7363" xml_f="7536" txt_i="2894" txt_f="3067"> and therefore possibly neutralizing the risk of relapse. The relapse rate for epithelial ovarian carcinoma in pathologic Complete Remission is generally between 42 and 44% </offsets><xref ref-type="bibr" rid="B12"><offsets xml_i="7568" xml_f="7570" txt_i="3067" txt_f="3069">12</offsets></xref><offsets xml_i="7577" xml_f="7578" txt_i="3069" txt_f="3070">-</offsets><xref ref-type="bibr" rid="B14"><offsets xml_i="7610" xml_f="7612" txt_i="3070" txt_f="3072">14</offsets></xref><offsets xml_i="7619" xml_f="7794" txt_i="3072" txt_f="3247">. Abdominal radiotherapy as consolidation treatment produced forms of gastrointestinal toxicity, such as subocclusion and enteritis, without significant therapeutic advantage </offsets><xref ref-type="bibr" rid="B15"><offsets xml_i="7826" xml_f="7828" txt_i="3247" txt_f="3249">15</offsets></xref><offsets xml_i="7835" xml_f="7836" txt_i="3249" txt_f="3250">-</offsets><xref ref-type="bibr" rid="B17"><offsets xml_i="7868" xml_f="7870" txt_i="3250" txt_f="3252">17</offsets></xref><offsets xml_i="7877" xml_f="7878" txt_i="3252" txt_f="3253">.</offsets></p><p><offsets xml_i="7885" xml_f="7945" txt_i="3254" txt_f="3314">In early ovarian cancer, adjuvant chemotherapy is effective </offsets><xref ref-type="bibr" rid="B18"><offsets xml_i="7977" xml_f="7979" txt_i="3314" txt_f="3316">18</offsets></xref><offsets xml_i="7986" xml_f="8403" txt_i="3316" txt_f="3733">; Trimbos et. al. reported results from a randomized trial, one conducted by the EORTC (European Organisation for Research and Treatment of Cancer) (ACTION Study) where immediate chemotherapy significantly improved recurrence-free survival with an absolute difference at five years of 8%, but with a greater advantage found among patients having had non-optimal staging or surgical treatment at inexperienced centers.</offsets></p><p><offsets xml_i="8410" xml_f="8663" txt_i="3734" txt_f="3987">However, other randomized studies have shown that disease-free survival and overall survival in advanced ovarian cancer do not vary in relation to the number of cycles of chemotherapy given, (6 vs. 9 cycles of PAC [Platinum-Adriamycin-Cyclophosphamide] </offsets><xref ref-type="bibr" rid="B19"><offsets xml_i="8695" xml_f="8697" txt_i="3987" txt_f="3989">19</offsets></xref><offsets xml_i="8704" xml_f="8757" txt_i="3989" txt_f="4042">, 5 vs. 10 cycles of polychemotherapy with Cisplatin </offsets><xref ref-type="bibr" rid="B20"><offsets xml_i="8789" xml_f="8791" txt_i="4042" txt_f="4044">20</offsets></xref><offsets xml_i="8798" xml_f="8823" txt_i="4044" txt_f="4069">, 6 vs. 12 cycles of PAC </offsets><xref ref-type="bibr" rid="B21"><offsets xml_i="8855" xml_f="8857" txt_i="4069" txt_f="4071">21</offsets></xref><offsets xml_i="8864" xml_f="8896" txt_i="4071" txt_f="4103"> or 5 vs. 8 courses of platinum </offsets><xref ref-type="bibr" rid="B22"><offsets xml_i="8928" xml_f="8930" txt_i="4103" txt_f="4105">22</offsets></xref><offsets xml_i="8937" xml_f="9042" txt_i="4105" txt_f="4207">), while still other trials on a small number of patients with absent disease or residuum &lt;2cm (table </offsets><xref ref-type="table" rid="T1"><offsets xml_i="9074" xml_f="9075" txt_i="4207" txt_f="4208">1</offsets></xref><offsets xml_i="9082" xml_f="9178" txt_i="4208" txt_f="4304">) would seem to confirm the usefulness of radiotherapy or of chemoradiotherapy as consolidation </offsets><xref ref-type="bibr" rid="B23"><offsets xml_i="9210" xml_f="9212" txt_i="4304" txt_f="4306">23</offsets></xref><offsets xml_i="9219" xml_f="9220" txt_i="4306" txt_f="4307">.</offsets></p></sec><sec sec-type="methods"><title><offsets xml_i="9261" xml_f="9284" txt_i="4309" txt_f="4332">2. Patients and Methods</offsets></title><p><offsets xml_i="9295" xml_f="10390" txt_i="4333" txt_f="5428">From October 1988 to October 1996, 122 patients affected by epithelial ovarian cancer who had been found to be in complete remission, as judged by laparoscopy and/or laparotomy, entered the GOCCNE study (Gruppo Oncologico Cooperativo Clinico del Nord-Est, consisting of 20 centers in North-east Italy) designed to evaluate the usefulness of consolidation chemotherapy in patients with pathologic complete remission. First-line chemotherapy consisted of Anthracyclin-Cyclophosphamide for 54 patients, Mitoxantrone-Carboplatin for 5 elderly patients and Cyclophosphamide-Platinum for 63 patients. Pathologic complete remission was assessed by CT scan in all patients; if this was negative, the same patients underwent laparoscopic control. All patients with negative laparotomy (70 pts; however, 1 pt. after a negative laparoscopy, at time of randomization resulted positive at second look laparotomy performed autonomously) and/or negative laparoscopic second looks (52 pts) were proposed for the study and randomly assigned to consolidation chemotherapy with 5-Fluorouracil + Cisplatin or nihil.</offsets></p><p><offsets xml_i="10397" xml_f="10923" txt_i="5429" txt_f="5940">Inclusion in the study was based on a histologically documented diagnosis, completion of first-line chemotherapy and a performance status higher than 60. In addition, it was required that patients have normal renal function (creatinine &lt;2 mg/dL, BUN &lt;45 mmol/L), hepatic function (conjugated bilirubin &lt;2 mg/dL, ALP &lt;150 U/L and γGT &lt;80 U/L) and cardiac function (as judged by physical examination, measurement of pulse and arterial pressure and ECG). Patients were also required to give their informed consent.</offsets></p><p><offsets xml_i="10930" xml_f="11019" txt_i="5941" txt_f="6027">Patients over 80 years of age were excluded, as were patients with WBC counts &lt;4000/mm</offsets><sup><offsets xml_i="11024" xml_f="11025" txt_i="6027" txt_f="6028">3</offsets></sup><offsets xml_i="11031" xml_f="11059" txt_i="6028" txt_f="6053"> or platelets &lt;140,000/mm</offsets><sup><offsets xml_i="11064" xml_f="11065" txt_i="6053" txt_f="6054">3</offsets></sup><offsets xml_i="11071" xml_f="11277" txt_i="6054" txt_f="6260">. Patients presenting with second tumors, psychiatric disorders, brain metastases and those with altered ECGs, suggesting important conduction disturbances (dromotropic or bathmotropic), were also excluded.</offsets></p><p><offsets xml_i="11284" xml_f="11378" txt_i="6261" txt_f="6355">Consolidation chemotherapy with 5-Fluorouracil (5-FU) and Cisplatin consisted of 5-FU 500 mg/m</offsets><sup><offsets xml_i="11383" xml_f="11384" txt_i="6355" txt_f="6356">2</offsets></sup><offsets xml_i="11390" xml_f="11464" txt_i="6356" txt_f="6430">/day intravenously for 5 days, followed by Cisplatin at a dose of 100 mg/m</offsets><sup><offsets xml_i="11469" xml_f="11470" txt_i="6430" txt_f="6431">2</offsets></sup><offsets xml_i="11476" xml_f="11485" txt_i="6431" txt_f="6440"> on the 6</offsets><sup><offsets xml_i="11490" xml_f="11492" txt_i="6440" txt_f="6442">th</offsets></sup><offsets xml_i="11498" xml_f="11503" txt_i="6442" txt_f="6447"> or 7</offsets><sup><offsets xml_i="11508" xml_f="11510" txt_i="6447" txt_f="6449">th</offsets></sup><offsets xml_i="11516" xml_f="11827" txt_i="6449" txt_f="6760"> day (never exceeding a total dose of 160 mg) associated with Allopurinol 300 mg/day. This was repeated every 28 days for 3 cycles. The choice of 5-Fluorouracil was based on the fact that 5-FU had been shown to be highly effective in salvage therapy for refractory ovarian cancer patients with low bulk disease </offsets><xref ref-type="bibr" rid="B24"><offsets xml_i="11859" xml_f="11861" txt_i="6760" txt_f="6762">24</offsets></xref><offsets xml_i="11868" xml_f="11870" txt_i="6762" txt_f="6764">, </offsets><xref ref-type="bibr" rid="B25"><offsets xml_i="11902" xml_f="11904" txt_i="6764" txt_f="6766">25</offsets></xref><offsets xml_i="11911" xml_f="11912" txt_i="6766" txt_f="6767">.</offsets></p><p><offsets xml_i="11919" xml_f="12405" txt_i="6768" txt_f="7251">In cases developing arterial hypertension or myocardiosclerosis (with diastolic pressure &gt;120mmHg) during treatment, the dose of 5-FU was reduced by 25%. The first day of 5-FU was abolished in cases of myelotoxicity protracted from the previous cycle (more than 5 weeks to recovery). Cisplatin was reduced by 50% in mononephric patients, or when obstructive nephropathy was encountered, as well as in cases of important hypacusia or neurotoxicity or in patients over 76 years of age.</offsets></p><p><offsets xml_i="12412" xml_f="12568" txt_i="7252" txt_f="7408">Statistical comparison of overall and disease-free survival was based on Kaplan-Meier estimates of survival and a log-rank test of statistical significance.</offsets></p></sec><sec sec-type="results"><title><offsets xml_i="12609" xml_f="12619" txt_i="7410" txt_f="7420">3. Results</offsets></title><p><offsets xml_i="12630" xml_f="13181" txt_i="7421" txt_f="7972">The study population consisted of 122 patients. Median age of both the consolidation therapy population and the nihil arm was 55 (range: 38-76 and 16-73, respectively). The stage distribution was 15 pts stage I C, 30 pts stage II B and II C, 71 pts stage III, and 5 pts stage IV; histologic grade was grade 1 in 19 cases, 2 in 45 cases and 3 in 57 cases. Distribution of histological grade for the Cisplatin arm vs. the nihil arm was grade 1-2 in 30 vs. 34 cases and grade 3 in 30 vs. 27 cases. Characteristics of the two groups can be found in table </offsets><xref ref-type="table" rid="T2"><offsets xml_i="13213" xml_f="13214" txt_i="7972" txt_f="7973">2</offsets></xref><offsets xml_i="13221" xml_f="13222" txt_i="7973" txt_f="7974">.</offsets></p><p><offsets xml_i="13229" xml_f="14005" txt_i="7975" txt_f="8751">The 61 patients in the nihil arm completed 5 cycles of first-line chemotherapy only, while an additional 3 cycles of polychemotherapy with FU followed by Cisplatin were proposed for the 61 patients in the Cisplatin arm. Of the 61 patients assigned to the Cisplatin arm, 47 (77.0%) completed 3 or more cycles. However, 4 patients (6.6%) completed only 1 cycle while 9 patients (14.8%) completed 2 cycles before suspending treatment (for noncompliance or for excessive gastrointestinal and/or neurological toxicity). One patient (1.6%) refused treatment entirely after randomization and is therefore not evaluable. Three of the 47 patients who completed 3 cycles continued treatment even further, receiving an additional 1-3 cycles of Cisplatin for a total of 4-6 cycles (table </offsets><xref ref-type="table" rid="T2"><offsets xml_i="14037" xml_f="14038" txt_i="8751" txt_f="8752">2</offsets></xref><offsets xml_i="14045" xml_f="14047" txt_i="8752" txt_f="8754">).</offsets></p><p><offsets xml_i="14054" xml_f="14462" txt_i="8755" txt_f="9163">The toxicity in treatment with Cisplatin consisted of nausea and vomiting in 38 patients (62.3% of Cisplatin-treated patients); this was WHO grade 3 in 17 pts (27.9%) and grade 4 in 10 pts (16.4%); it was neurological in 21 pts (34.4%), and consisted of leukopenia in 13 pts (21.3%), mucositis in 7 pts (11.5%), nephrotoxicity in 4 pts (6.6%), infection in 3 (4.9%) and anemia in another 2 (3.3%) pts (table </offsets><xref ref-type="table" rid="T3"><offsets xml_i="14494" xml_f="14495" txt_i="9163" txt_f="9164">3</offsets></xref><offsets xml_i="14502" xml_f="14504" txt_i="9164" txt_f="9166">).</offsets></p><p><offsets xml_i="14511" xml_f="14572" txt_i="9167" txt_f="9228">The overall survival of the two groups was very similar (fig.</offsets><xref ref-type="fig" rid="F1"><offsets xml_i="14602" xml_f="14603" txt_i="9228" txt_f="9229">1</offsets></xref><offsets xml_i="14610" xml_f="15195" txt_i="9229" txt_f="9814">.). There were 36 relapses (59.0%) in the Cisplatin arm and 30 (49.2%) in the “nihil” arm. Peritoneal relapses varied for the two arms and were 15 (25%) for Cisplatin vs. 10 (16.4%) for nihil. Relapses in the vaginal dome were found in 1 case (1.7%) treated with Cisplatin and 5 (8.2%) in the nihil arm, while hepatic and splenic relapses were nearly identical. Relapses in lung-pleura were also similar: 5 (8.3%) in the Cisplatin arm vs. 6 (9.8%) in the nihil arm. Relapses in lumboaortic-inguinal lymph nodes were 11 (18.0%) in the Cisplatin arm and 4 (6.6%) in the nihil arm (table </offsets><xref ref-type="table" rid="T4"><offsets xml_i="15227" xml_f="15228" txt_i="9814" txt_f="9815">4</offsets></xref><offsets xml_i="15235" xml_f="15237" txt_i="9815" txt_f="9817">).</offsets></p><p><offsets xml_i="15244" xml_f="15712" txt_i="9818" txt_f="10286">Seven patients presented a second neoplasm after treatment for ovarian cancer. There were two cases of breast cancer, two cases of sigmoid adenocarcinoma, one case of small cell lung cancer, one case of hypernephroma, and one case of head and neck cancer. Six of these patients were in the nihil arm. Only one patient (head and neck cancer) was in the Cisplatin arm. Death in these patients resulted from the second neoplasm and not from progression of ovarian cancer.</offsets></p><p><offsets xml_i="15719" xml_f="16177" txt_i="10287" txt_f="10745">Median overall survival was 87 months for the cisplatin arm (82.0% at 3 years) and 89 months for the nihil arm (80.3% at 3 years) (p=0.66, log rank test). Median disease free survival was 68 months (range 1.4-170.0) for the Cisplatin arm (62.1% at three years for the cisplatin arm) and 73 months (range 1.6-169.5) for the nihil arm (62.3% at three years for the nihil arm). There was no statistical difference between the two groups (p=0.41, log rank test).</offsets></p></sec><sec sec-type="discussion"><title><offsets xml_i="16221" xml_f="16234" txt_i="10747" txt_f="10760">4. Discussion</offsets></title><p><offsets xml_i="16245" xml_f="16555" txt_i="10761" txt_f="11071">Ovarian cancer patients have high response rates to initial chemotherapy after cytoreductive surgery. There are fewer complete responses with the use of anthracyclin and alkylating agents as first-line treatment, although their duration is greater than the complete responses obtained by platinum chemotherapy </offsets><xref ref-type="bibr" rid="B5"><offsets xml_i="16586" xml_f="16587" txt_i="11071" txt_f="11072">5</offsets></xref><offsets xml_i="16594" xml_f="16656" txt_i="11072" txt_f="11134">. Relapses occur in 30% of the cases within the first 3 years </offsets><xref ref-type="bibr" rid="B26"><offsets xml_i="16688" xml_f="16690" txt_i="11134" txt_f="11136">26</offsets></xref><offsets xml_i="16697" xml_f="16896" txt_i="11136" txt_f="11335">. It is thus possible that the use of alkylating agents and anthracyclins could select responders who have a different prognosis from patients treated with a platinum-based regime. Unlike Gershenson </offsets><xref ref-type="bibr" rid="B27"><offsets xml_i="16928" xml_f="16930" txt_i="11335" txt_f="11337">27</offsets></xref><offsets xml_i="16937" xml_f="17114" txt_i="11337" txt_f="11514"> who sustains the usefulness of prolonged chemotherapy with platinum, other investigators have found that prolonging chemotherapy does not have any benefit in terms of survival </offsets><xref ref-type="bibr" rid="B19"><offsets xml_i="17146" xml_f="17148" txt_i="11514" txt_f="11516">19</offsets></xref><offsets xml_i="17155" xml_f="17156" txt_i="11516" txt_f="11517">-</offsets><xref ref-type="bibr" rid="B22"><offsets xml_i="17188" xml_f="17190" txt_i="11517" txt_f="11519">22</offsets></xref><offsets xml_i="17197" xml_f="17198" txt_i="11519" txt_f="11520">.</offsets></p><p><offsets xml_i="17205" xml_f="17536" txt_i="11521" txt_f="11852">In the literature there is no agreement regarding treatment of patients with ovarian cancer who are in complete remission following first-line chemotherapy, and no therapeutic modality shows a clear and definite advantage in terms of disease-free survival. Moreover, there are no large comparative randomized studies on this topic </offsets><xref ref-type="bibr" rid="B19"><offsets xml_i="17568" xml_f="17570" txt_i="11852" txt_f="11854">19</offsets></xref><offsets xml_i="17577" xml_f="17578" txt_i="11854" txt_f="11855">-</offsets><xref ref-type="bibr" rid="B21"><offsets xml_i="17610" xml_f="17612" txt_i="11855" txt_f="11857">21</offsets></xref><offsets xml_i="17619" xml_f="17621" txt_i="11857" txt_f="11859">, </offsets><xref ref-type="bibr" rid="B26"><offsets xml_i="17653" xml_f="17655" txt_i="11859" txt_f="11861">26</offsets></xref><offsets xml_i="17662" xml_f="17663" txt_i="11861" txt_f="11862">.</offsets></p><p><offsets xml_i="17670" xml_f="18087" txt_i="11863" txt_f="12280">In 1988 when the present trial was proposed there was uncertainty as to whether 3 additional courses of platinum based chemotherapy were useful in patients who had obtained complete remission after 5 courses of first-line chemotherapy with or without Cisplatin. The choice of Cisplatin + 5-FU was based on the fact that other drugs such liposomal Doxorubicin, Paclitaxel, or Topotecan were not available at that time.</offsets></p><p><offsets xml_i="18094" xml_f="18251" txt_i="12281" txt_f="12438">Radiation therapy was not chosen for consolidation treatment because the literature provided no studies to support a significant advantage over chemotherapy </offsets><xref ref-type="bibr" rid="B26"><offsets xml_i="18283" xml_f="18285" txt_i="12438" txt_f="12440">26</offsets></xref><offsets xml_i="18292" xml_f="18294" txt_i="12440" txt_f="12442">, </offsets><xref ref-type="bibr" rid="B28"><offsets xml_i="18326" xml_f="18328" txt_i="12442" txt_f="12444">28</offsets></xref><offsets xml_i="18335" xml_f="18337" txt_i="12444" txt_f="12446">, </offsets><xref ref-type="bibr" rid="B29"><offsets xml_i="18369" xml_f="18371" txt_i="12446" txt_f="12448">29</offsets></xref><offsets xml_i="18378" xml_f="18433" txt_i="12448" txt_f="12503"> while presenting local toxicity. Still, Pickle et al. </offsets><xref ref-type="bibr" rid="B23"><offsets xml_i="18465" xml_f="18467" txt_i="12503" txt_f="12505">23</offsets></xref><offsets xml_i="18474" xml_f="18975" txt_i="12505" txt_f="13006">, in a randomized study, demonstrated the usefulness of radiation therapy in association with chemotherapy in patients (predominantly stage III) who were judged free of disease, after radical surgery and six cycles of first-line chemotherapy, with respect to thirty-two patients who received only whole abdominal radiation following surgery. The overall and relapse-free survival was better for the group receiving combination chemo-radiotherapy, confirming the fundamental role of systemic treatment.</offsets></p><p><offsets xml_i="18982" xml_f="19334" txt_i="13007" txt_f="13359">Our experience with only 121 evaluable patients, however, suggests that there is no difference between chemotherapeutic consolidation after remission vs. nihil. This trial therefore seems to confirm the findings of other authors, namely that the 5-year-survival of patients without residual tumor mass following first surgery varies between 50 and 70% </offsets><xref ref-type="bibr" rid="B3"><offsets xml_i="19365" xml_f="19366" txt_i="13359" txt_f="13360">3</offsets></xref><offsets xml_i="19373" xml_f="19375" txt_i="13360" txt_f="13362">, </offsets><xref ref-type="bibr" rid="B30"><offsets xml_i="19407" xml_f="19409" txt_i="13362" txt_f="13364">30</offsets></xref><offsets xml_i="19416" xml_f="19603" txt_i="13364" txt_f="13548">, and that their survival is better than that of patients with residual mass &lt;2 cm (which varies between 35-55%) or patients with residuum of 2 cm or more (which varies between 0-30%) </offsets><xref ref-type="bibr" rid="B3"><offsets xml_i="19634" xml_f="19635" txt_i="13548" txt_f="13549">3</offsets></xref><offsets xml_i="19642" xml_f="19644" txt_i="13549" txt_f="13551">, </offsets><xref ref-type="bibr" rid="B7"><offsets xml_i="19675" xml_f="19676" txt_i="13551" txt_f="13552">7</offsets></xref><offsets xml_i="19683" xml_f="19684" txt_i="13552" txt_f="13553">.</offsets></p><p><offsets xml_i="19691" xml_f="19806" txt_i="13554" txt_f="13669">While statistical analysis of the present study does not note any significant difference in overall survival (fig. </offsets><xref ref-type="fig" rid="F1"><offsets xml_i="19836" xml_f="19837" txt_i="13669" txt_f="13670">1</offsets></xref><offsets xml_i="19844" xml_f="19880" txt_i="13670" txt_f="13706">) or in disease-free survival (fig. </offsets><xref ref-type="fig" rid="F2"><offsets xml_i="19910" xml_f="19911" txt_i="13706" txt_f="13707">2</offsets></xref><offsets xml_i="19918" xml_f="20137" txt_i="13707" txt_f="13926">) between the two arms suggesting that polychemotherapy with cisplatin is not very effective in a consolidative setting, it is limited by the lack of stratification by stage, and by previous type of chemotherapy (table </offsets><xref ref-type="table" rid="T2"><offsets xml_i="20169" xml_f="20170" txt_i="13926" txt_f="13927">2</offsets></xref><offsets xml_i="20177" xml_f="20472" txt_i="13927" txt_f="14222">) as well as by the limited number of patients randomized (122 pts). The lack of stratification might have resulted in the selection of a population with better prognostic factors in the nihil arm vs. the Cisplatin arm, thereby creating a bias; thus, this result should be evaluated with caution</offsets></p><p><offsets xml_i="20479" xml_f="20764" txt_i="14223" txt_f="14508">It is worth noting that many of our patients had not been previously treated with platinum, and yet survival rates were similar to those for patients with platinum based first-line therapy. This would seem to cast doubts on the long-term efficacy of platinum therapy in ovarian cancer.</offsets></p><p><offsets xml_i="20771" xml_f="21426" txt_i="14509" txt_f="15164">In our study severe toxicity was rare with the exception of grade 3-4 emesis encountered in 44,3%. Severe nausea was controlled in most of the patients; however, in 21.3% of patients toxicity was severe enough to suspend treatment either for non-compliance or for excessive gastrointestinal toxicity, thus cycles were suspended in 13 patients (4 after completing only one cycle, while 9 refused further treatment after completing the second cycle). Our patients did not experience severe neuropathy. In addition, severe events such as sepsis or hematologic toxicity were also uncommon in our study with the exception of 1 case of grade 4 thrombocytopenia.</offsets></p><p><offsets xml_i="21433" xml_f="21743" txt_i="15165" txt_f="15475">Oddly, there were more relapses in lumboaortic-inguinal lymph nodes in the chemotherapy arm, however, in this study the different distribution of patients with regard to residuum and stage, which resulted from a lack of stratification, might have produced a lack of benefit in terms of recurrence and survival.</offsets></p><p><offsets xml_i="21750" xml_f="21882" txt_i="15476" txt_f="15608">Currently, tumor cell heterogeneity and clonal selection of resistant tumor cells continue to be major obstacles in cancer therapy. </offsets><italic><offsets xml_i="21890" xml_f="21898" txt_i="15608" txt_f="15616">In vitro</offsets></italic><offsets xml_i="21907" xml_f="22014" txt_i="15616" txt_f="15723"> experimental studies are limited in that they cannot represent the heterogeneity of cancer cells observed </offsets><italic><offsets xml_i="22022" xml_f="22029" txt_i="15723" txt_f="15730">in vivo</offsets></italic><offsets xml_i="22038" xml_f="22151" txt_i="15730" txt_f="15843">. On the other hand, some immunohistochemical correlation with clinical aspects of disease is starting to emerge </offsets><xref ref-type="bibr" rid="B31"><offsets xml_i="22183" xml_f="22185" txt_i="15843" txt_f="15845">31</offsets></xref><offsets xml_i="22192" xml_f="22194" txt_i="15845" txt_f="15847">, </offsets><xref ref-type="bibr" rid="B32"><offsets xml_i="22226" xml_f="22228" txt_i="15847" txt_f="15849">32</offsets></xref><offsets xml_i="22235" xml_f="22237" txt_i="15849" txt_f="15851">, </offsets><xref ref-type="bibr" rid="B33"><offsets xml_i="22269" xml_f="22271" txt_i="15851" txt_f="15853">33</offsets></xref><offsets xml_i="22278" xml_f="22280" txt_i="15853" txt_f="15855">, </offsets><xref ref-type="bibr" rid="B34"><offsets xml_i="22312" xml_f="22314" txt_i="15855" txt_f="15857">34</offsets></xref><offsets xml_i="22321" xml_f="23063" txt_i="15857" txt_f="16596"> and may eventually provide clues for further tailoring of therapy to the specific patient. In addition, in programming new therapeutic approaches it is necessary to understand the percentage of relapses after complete remission that are due to residual tumor cells and how many might be due to a perpetuation of carcinogenesis in the peritoneal cavity. To date, the most important variable in survival of patients with epithelial ovarian cancer is residual disease &gt; 10 cm after first surgery; these patients present with an extremely high relapse rate. Thus, “wait and see” is still the main choice for patients who have reached complete remission after first-line chemotherapy in the absence of confirmatory data from randomized trials.</offsets></p></sec></body><back><ref-list><ref id="B1"><label>1</label><citation citation-type="journal"><name><surname>Fuks</surname><given-names>Z</given-names></name><article-title>External radiotherapy of ovarian cancer: Standard approaches and new frontiers</article-title><source>Semin Oncol</source><year>1975</year><volume>2</volume><fpage>253</fpage><lpage>266</lpage><pub-id pub-id-type="pmid">1234806</pub-id></citation></ref><ref id="B2"><label>2</label><citation citation-type="journal"><name><surname>Dembo</surname><given-names>AJ</given-names></name><article-title>Radiotherapeutic management of ovarian cancer</article-title><source>Semin Oncol</source><year>1984</year><volume>11</volume><fpage>238</fpage><lpage>250</lpage><pub-id pub-id-type="pmid">6435249</pub-id></citation></ref><ref id="B3"><label>3</label><citation citation-type="journal"><name><surname>Martinez</surname><given-names>A</given-names></name><name><surname>Schray</surname><given-names>MF</given-names></name><name><surname>Howes</surname><given-names>AE</given-names></name><article-title>Postoperative radiation therapy for epithelial ovarian cancer: the curative role based on a 24-years experience</article-title><source>J Clin Oncol</source><year>1985</year><volume>3</volume><fpage>901</fpage><lpage>922</lpage><pub-id pub-id-type="pmid">3926956</pub-id></citation></ref><ref id="B4"><label>4</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Fuks</surname><given-names>Z</given-names></name><name><surname>Yahalom</surname><given-names>Y</given-names></name><name><surname>Brenner</surname><given-names>H</given-names></name></person-group><article-title>The treatment of ovarian carcinoma</article-title><person-group person-group-type="editor"><name><surname>Nori</surname><given-names>D</given-names></name><name><surname>Hilaris</surname><given-names>BS</given-names></name></person-group><source>Radiation Therapy of Gynecological Cancer</source><publisher-loc>New York</publisher-loc><publisher-name>Liss</publisher-name><year>1987</year><fpage>147</fpage><lpage>172</lpage></citation></ref><ref id="B5"><label>5</label><citation citation-type="journal"><name><surname>Wiltshaw</surname><given-names>E</given-names></name><name><surname>Evans</surname><given-names>B</given-names></name><name><surname>Rustin</surname><given-names>G</given-names></name><article-title>A prospective randomized trial comparing high-dose cisplatin with low-dose cisplatin and chlorambucil in advanced ovarian carcinoma</article-title><source>J Clin Oncol</source><year>1986</year><volume>4</volume><fpage>722</fpage><lpage>729</lpage><pub-id pub-id-type="pmid">3517243</pub-id></citation></ref><ref id="B6"><label>6</label><citation citation-type="journal"><name><surname>Parker</surname><given-names>LM</given-names></name><name><surname>Griffiths</surname><given-names>CT</given-names></name><name><surname>Yankee</surname><given-names>RA</given-names></name><article-title>Combination chemotherapy with Adriamycin-cyclophosphamide of advanced ovarian carcinoma</article-title><source>Cancer</source><year>1980</year><volume>46</volume><fpage>669</fpage><lpage>674</lpage><pub-id pub-id-type="pmid">7397632</pub-id></citation></ref><ref id="B7"><label>7</label><citation citation-type="journal"><name><surname>Wharton</surname><given-names>JT</given-names></name><name><surname>Edwards</surname><given-names>CL</given-names></name><name><surname>Rutledge</surname><given-names>FN</given-names></name><article-title>Long term survival after chemotherapy for advanced epithelial ovarian carcinoma</article-title><source>Am J Obstet Gynecol</source><year>1984</year><volume>148</volume><fpage>997</fpage><lpage>1005</lpage><pub-id pub-id-type="pmid">6369990</pub-id></citation></ref><ref id="B8"><label>8</label><citation citation-type="journal"><name><surname>Williams</surname><given-names>CJ</given-names></name><name><surname>Mead</surname><given-names>GM</given-names></name><name><surname>Macbeth</surname><given-names>RF</given-names></name><article-title>Cisplatin combination chemotherapy versus chlorambucil in advanced ovarian carcinoma: mature results of randomized study</article-title><source>J Clin Oncol</source><year>1985</year><volume>3</volume><fpage>1455</fpage><lpage>1462</lpage><pub-id pub-id-type="pmid">3903062</pub-id></citation></ref><ref id="B9"><label>9</label><citation citation-type="journal"><name><surname>Louie</surname><given-names>KG</given-names></name><name><surname>Ozols</surname><given-names>RF</given-names></name><name><surname>Myers</surname><given-names>CE</given-names></name><article-title>Long-term results of a cisplatin-containing combination chemotherapy regimen for the treatment of advanced ovarian carcinoma</article-title><source>J Clin Oncol</source><year>1986</year><volume>4</volume><fpage>1579</fpage><lpage>1585</lpage><pub-id pub-id-type="pmid">3095501</pub-id></citation></ref><ref id="B10"><label>10</label><citation citation-type="journal"><name><surname>Bristow</surname><given-names>RS</given-names></name><name><surname>Tomacruz</surname><given-names>DK</given-names></name><name><surname>Armstrong</surname><given-names>EL</given-names></name><etal></etal><article-title>Survival impact of maximum cytoreductive surgery for advanced ovarian carcinoma during the platinum-era: a meta-analysis of 6,848 patients</article-title><source>Proc ASCO</source><year>2001</year><volume>20</volume><issue>1</issue><fpage>202a</fpage></citation></ref><ref id="B11"><label>11</label><citation citation-type="journal"><name><surname>Greco</surname><given-names>FA</given-names></name><name><surname>Hande</surname><given-names>KR</given-names></name><name><surname>Jones</surname><given-names>HW</given-names></name><etal></etal><article-title>Advanced ovarian cancer: long-term follow up after brief intensive chemotherapy</article-title><source>Proc ASCO</source><year>1984</year><volume>3</volume><fpage>166</fpage></citation></ref><ref id="B12"><label>12</label><citation citation-type="journal"><name><surname>Rubin</surname><given-names>SC</given-names></name><name><surname>Hoskins</surname><given-names>WJ</given-names></name><name><surname>Saigo</surname><given-names>PE</given-names></name><etal></etal><article-title>Prognostic factors for recurrence following negative second-look laparotomy in ovarian cancer patients with platinum-based chemotherapy</article-title><source>Gynecol Oncol</source><year>1991</year><volume>42</volume><issue>2</issue><fpage>137</fpage><lpage>141</lpage><pub-id pub-id-type="pmid">1894172</pub-id></citation></ref><ref id="B13"><label>13</label><citation citation-type="journal"><name><surname>Neijt</surname><given-names>JP</given-names></name><article-title>Treatment of advanced ovarian cancer: 10 years of experience</article-title><source>Ann Oncol</source><year>1992</year><volume>3</volume><fpage>17</fpage><lpage>27</lpage><pub-id pub-id-type="pmid">1606064</pub-id></citation></ref><ref id="B14"><label>14</label><citation citation-type="journal"><name><surname>Luesley</surname><given-names>D</given-names></name><name><surname>Blackledge</surname><given-names>G</given-names></name><name><surname>Kelly</surname><given-names>K</given-names></name><etal></etal><article-title>Failure of second-look laparotomy to influence survival in epithelial ovarian cancer</article-title><source>The Lancet</source><year>1988</year><volume>10</volume><fpage>599</fpage><lpage>603</lpage></citation></ref><ref id="B15"><label>15</label><citation citation-type="journal"><name><surname>Hainsworth</surname><given-names>JD</given-names></name><name><surname>Malcom</surname><given-names>A</given-names></name><name><surname>Johnson</surname><given-names>DH</given-names></name><etal></etal><article-title>Advanced minimal residual ovarian carcinoma: abdominopelvic irradiation following combination chemotherapy</article-title><source>Obstet Gynecol</source><year>1983</year><volume>61</volume><issue>5</issue><fpage>619</fpage><lpage>623</lpage><pub-id pub-id-type="pmid">6403897</pub-id></citation></ref><ref id="B16"><label>16</label><citation citation-type="journal"><name><surname>Fuks</surname><given-names>Z</given-names></name><name><surname>Rizel</surname><given-names>S</given-names></name><name><surname>Biran</surname><given-names>S</given-names></name><article-title>Chemotherapeutic and surgical induction of pathological complete remission and whole abdominal irradiation for consolidation does not enhance the cure of stage III ovarian carcinoma</article-title><source>J Clin Oncol</source><year>1988</year><volume>6</volume><fpage>509</fpage><lpage>516</lpage><pub-id pub-id-type="pmid">3127551</pub-id></citation></ref><ref id="B17"><label>17</label><citation citation-type="journal"><name><surname>Hoffman</surname><given-names>MS</given-names></name><name><surname>Greenberg</surname><given-names>H</given-names></name><name><surname>Finan</surname><given-names>M</given-names></name><etal></etal><article-title>Whole-abdomen radiation as a second-line therapy for epithelial ovarian cancer</article-title><source>Gynecol Oncol</source><year>1989</year><volume>35</volume><issue>1</issue><fpage>73</fpage><lpage>74</lpage><pub-id pub-id-type="pmid">2792906</pub-id></citation></ref><ref id="B18"><label>18</label><citation citation-type="journal"><name><surname>Trimbos</surname><given-names>BJ</given-names></name><name><surname>Vergote</surname><given-names>I</given-names></name><name><surname>Bolis</surname><given-names>G</given-names></name><etal></etal><article-title>Impact of Adjuvant Chemotherapy and Surgical Staging in Early-Stage Ovarian Carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm Trial</article-title><source>J Natl Cancer Inst</source><year>2003</year><volume>95</volume><issue>2</issue><fpage>113</fpage><lpage>125</lpage><pub-id pub-id-type="pmid">12529344</pub-id></citation></ref><ref id="B19"><label>19</label><citation citation-type="journal"><name><surname>Watring</surname><given-names>W</given-names></name><name><surname>Semrad</surname><given-names>N</given-names></name><name><surname>Alverdian</surname><given-names>V</given-names></name><etal></etal><article-title>Second-look procedures in ovarian cancer patients receiving six vs</article-title><source>nine courses of platinum, adriamycin, cytoxan (PAC) chemotherapy: the SCPMG experience 1982-1985. Gynecol Oncol</source><year>1989</year><volume>32</volume><issue>2</issue><fpage>245</fpage><lpage>247</lpage></citation></ref><ref id="B20"><label>20</label><citation citation-type="journal"><name><surname>Hakes</surname><given-names>TB</given-names></name><name><surname>Chalas</surname><given-names>E</given-names></name><name><surname>Hoskins</surname><given-names>WJ</given-names></name><etal></etal><article-title>Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin and cisplatin in advanced ovarian carcinoma</article-title><source>Gynecol Oncol</source><year>1992</year><volume>45</volume><issue>3</issue><fpage>284</fpage><lpage>289</lpage><pub-id pub-id-type="pmid">1612505</pub-id></citation></ref><ref id="B21"><label>21</label><citation citation-type="journal"><name><surname>Bertelsen</surname><given-names>K</given-names></name><name><surname>Jakobsen</surname><given-names>A</given-names></name><name><surname>Stroyer</surname><given-names>I</given-names></name><etal></etal><article-title>A prospective randomized comparison of 6 and 12 cycles of Cyclophosphamide, Adriamycin and Cisplatin in advanced epithelial ovarian cancer: a Danish ovarian study Group Trial (DACOVA)</article-title><source>Gynecol Oncol</source><year>1993</year><volume>49</volume><fpage>30</fpage><lpage>36</lpage><pub-id pub-id-type="pmid">8482557</pub-id></citation></ref><ref id="B22"><label>22</label><citation citation-type="journal"><name><surname>Lambert</surname><given-names>HE</given-names></name><name><surname>Rustin</surname><given-names>GJS</given-names></name><name><surname>Gregory</surname><given-names>WM</given-names></name><etal></etal><article-title>A randomized trial of five versus eight courses of cisplatin or carboplatin advanced ovarian carcinoma: a North Themes Ovary Group study</article-title><source>Ann Oncol</source><year>1997</year><volume>8</volume><fpage>327</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">9209661</pub-id></citation></ref><ref id="B23"><label>23</label><citation citation-type="journal"><name><surname>Pickel</surname><given-names>H</given-names></name><name><surname>Lahousen</surname><given-names>M</given-names></name><name><surname>Petru</surname><given-names>E</given-names></name><etal></etal><article-title>Consolidation radiotherapy after carboplatin-based chemotherapy in radically operated advanced ovarian cancer</article-title><source>Gynecol Oncol</source><year>1999</year><volume>72</volume><fpage>215</fpage><lpage>219</lpage><pub-id pub-id-type="pmid">10021304</pub-id></citation></ref><ref id="B24"><label>24</label><citation citation-type="journal"><name><surname>Doroshow</surname><given-names>J</given-names></name><name><surname>Braly</surname><given-names>P</given-names></name><name><surname>Hoff</surname><given-names>S</given-names></name><etal></etal><article-title>Intraperitoneal chemotherapy with cisplatin and 5-fluorouracil: an active regimen for refractory ovarian cancer</article-title><source>Proc ASCO</source><year>1986</year><volume>5</volume><fpage>117</fpage></citation></ref><ref id="B25"><label>25</label><citation citation-type="confproc"><person-group person-group-type="author"><name><surname>Fiorentino</surname><given-names>MV</given-names></name><name><surname>Nicoletto</surname><given-names>MO</given-names></name><name><surname>Smergo</surname><given-names>A</given-names></name><etal></etal></person-group><article-title>5-Fluorouracil and platin as second line in ovarian cancer</article-title><source>Second International Symposium on “Multimodality of treatment in Ovarian Cancer”</source><conf-date>1987, September 24-26</conf-date><conf-loc>Genoa, Italy</conf-loc></citation></ref><ref id="B26"><label>26</label><citation citation-type="journal"><name><surname>Goldhirsch</surname><given-names>A</given-names></name><name><surname>Greiner</surname><given-names>R</given-names></name><name><surname>Dreher</surname><given-names>E</given-names></name><etal></etal><article-title>Treatment of advanced ovarian cancer with surgery, chemotherapy, and consolidation of response by whole-abdominal radiotherapy</article-title><source>Cancer</source><year>1988</year><volume>62</volume><fpage>40</fpage><lpage>47</lpage><pub-id pub-id-type="pmid">3133102</pub-id></citation></ref><ref id="B27"><label>27</label><citation citation-type="journal"><name><surname>Gershenson</surname><given-names>DM</given-names></name><name><surname>Mitchell</surname><given-names>MF</given-names></name><name><surname>Atkinson</surname><given-names>N</given-names></name><etal></etal><article-title>The effect of prolonged cisplatin-based chemotherapy on progression-free survival in patients with optimal epithelial ovarian cancer: “maintenance” therapy reconsidered</article-title><source>Gynecol Oncol</source><year>1992</year><volume>47</volume><fpage>7</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">1427404</pub-id></citation></ref><ref id="B28"><label>28</label><citation citation-type="journal"><name><surname>Menczer</surname><given-names>J</given-names></name><name><surname>Ben-Baruch</surname><given-names>G</given-names></name><name><surname>Modan</surname><given-names>M</given-names></name><etal></etal><article-title>Intraperitoneal cisplatin chemotherapy versus abdominopelvic irradiation in ovarian carcinoma patients after second-look laparotomy</article-title><source>Cancer</source><year>1989</year><volume>63</volume><fpage>1509</fpage><lpage>1513</lpage><pub-id pub-id-type="pmid">2924259</pub-id></citation></ref><ref id="B29"><label>29</label><citation citation-type="journal"><name><surname>Menczer</surname><given-names>J</given-names></name><name><surname>Ben-Baruch</surname><given-names>G</given-names></name><name><surname>Rizel</surname><given-names>S</given-names></name><etal></etal><article-title>Intraperitoneal chemotherapy with cisplatin and etoposide in ovarian carcinoma patients who are clinically in complete remission</article-title><source>Eur J Gynaecol Oncol</source><year>1995</year><volume>16</volume><issue>1</issue><fpage>12</fpage><lpage>17</lpage><pub-id pub-id-type="pmid">7744111</pub-id></citation></ref><ref id="B30"><label>30</label><citation citation-type="journal"><name><surname>Dembo</surname><given-names>AJ</given-names></name><article-title>Abdominopelvic radiotherapy in ovarian cancer</article-title><source>A 10-years experience. Cancer</source><year>1985</year><volume>55</volume><fpage>2285</fpage><lpage>2290</lpage></citation></ref><ref id="B31"><label>31</label><citation citation-type="journal"><name><surname>Baekelandt</surname><given-names>MM</given-names></name><name><surname>Holm</surname><given-names>R</given-names></name><name><surname>Nesland</surname><given-names>JM</given-names></name><etal></etal><article-title>P-glycoprotein expression is a marker for chemotherapy resistance and prognosis in advanced ovarian cancer</article-title><source>Anticancer Res</source><year>2000</year><volume>20</volume><issue>2B</issue><fpage>1061</fpage><lpage>1067</lpage><pub-id pub-id-type="pmid">10810398</pub-id></citation></ref><ref id="B32"><label>32</label><citation citation-type="journal"><name><surname>Xiang</surname><given-names>J</given-names></name><name><surname>Gomez-Navarro</surname><given-names>J</given-names></name><name><surname>Arafat</surname><given-names>W</given-names></name><etal></etal><article-title>Pro-apoptotis treatment with adenovirus encoding Bax enhances the effect of chemotherapy in ovarian cancer</article-title><source>J Gene Med</source><year>2000</year><volume>2</volume><issue>2</issue><fpage>97</fpage><lpage>106</lpage><pub-id pub-id-type="pmid">10809143</pub-id></citation></ref><ref id="B33"><label>33</label><citation citation-type="journal"><name><surname>Petty</surname><given-names>R</given-names></name><name><surname>Evans</surname><given-names>A</given-names></name><name><surname>Duncan</surname><given-names>I</given-names></name><etal></etal><article-title>Drug resistance in ovarian cancer - the role of p53</article-title><source>Pathol Oncol Res</source><year>1998</year><volume>4</volume><issue>2</issue><fpage>97</fpage><lpage>102</lpage><pub-id pub-id-type="pmid">9654593</pub-id></citation></ref><ref id="B34"><label>34</label><citation citation-type="journal"><name><surname>Skirnisdottir</surname><given-names>I</given-names></name><name><surname>Seidal</surname><given-names>T</given-names></name><name><surname>Gerdin</surname><given-names>E</given-names></name><name><surname>Soreb</surname><given-names>B</given-names></name><article-title>The prognostic importance of p53, bcl-2, and bax in early stage epithelial ovarian carcinoma treated with adjuvant chemotherapy</article-title><source>Int J Gynecol Cancer</source><year>2002</year><volume>12</volume><fpage>265</fpage><lpage>276</lpage><pub-id pub-id-type="pmid">12060448</pub-id></citation></ref><ref id="B35"><label>35</label><citation citation-type="journal"><name><surname>Falcone</surname><given-names>A</given-names></name><name><surname>Chiara</surname><given-names>S</given-names></name><name><surname>Franzone</surname><given-names>P</given-names></name><etal></etal><article-title>Moving-strip abdomino-pelvic radiotherapy after cis-platinum-based chemotherapy and second-look operation</article-title><source>A feasibility study in advanced ovarian cancer. Am J Clin Oncol</source><year>1988</year><volume>11</volume><issue>1</issue><fpage>16</fpage><lpage>20</lpage></citation></ref><ref id="B36"><label>36</label><citation citation-type="journal"><name><surname>Nicoletto</surname><given-names>MO</given-names></name><name><surname>Fiorentino</surname><given-names>M</given-names></name><name><surname>Vinante</surname><given-names>O</given-names></name><etal></etal><article-title>Experience with intraperitoneal alpha-2a interferon</article-title><source>Oncology</source><year>1992</year><volume>49</volume><fpage>467</fpage><lpage>473</lpage><pub-id pub-id-type="pmid">1465286</pub-id></citation></ref><ref id="B37"><label>37</label><citation citation-type="journal"><name><surname>Barakat</surname><given-names>RR</given-names></name><name><surname>Almadrones</surname><given-names>L</given-names></name><name><surname>Venkatraman</surname><given-names>ES</given-names></name><etal></etal><article-title>A phase II trial of intraperitoneal cisplatin and etoposide as consolidation therapy in patients with stage II-IV epithelial ovarian cancer following negative surgical assessment</article-title><source>Gynecol Oncol</source><year>1998</year><volume>69</volume><fpage>17</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">9570993</pub-id></citation></ref></ref-list><bio id="bio1"><p><bold>M. O. Nicoletto</bold> is the Associate Medical Director of the Division of Medical Oncology at the Civil Hospital of Padua, Italy. At present, her duties include teaching in the Oncology Residency program. She is the coordinator of the Gruppo Oncologico-Clinico-Nord-Est-Ovarian-Cancer (GOCNE). She is also responsible for the local screening group for hereditary tumors, and cooperates with national and international ICON studies. Her primary research interests are ovarian cancer and hereditary breast-ovarian neoplasms.</p></bio><bio id="bio2"><p><bold>S. Tumolo</bold> is currently the Chief of the Oncology Unit at “Santa Maria degli Angeli” Hospital in Pordenone, Italy. His past positions include full-time associate at the Division of Radiotherapy and Medical Oncology, Ospedale Civile in Pordenone, for 6 years and at the Division of Medical Oncology, Centro di Riferimento Oncologico, in Aviano, for 13 years. He is actively involved in various areas of research, in the past as a member of the Gynaecological Cancer Group of the European Organization for Research and Treatment of Cancer (EORTC).</p></bio><bio id="bio3"><p><bold>C. Falci</bold> recently finished her Medical Degree at the University of Padua with a thesis in collaboration with the Mario Negri Institute in Milan and continues to cooperate with the ICON studies.</p></bio><bio id="bio4"><p><bold>M. Donach</bold>, having completed his B.A. in Biochemistry at New York University, is presently in his final year of medical studies at the University of Padua and will pursue resident training in Oncology. His current interests include cancer cell biology and research in the field of ovarian cancer.</p></bio><sec sec-type="display-objects"><title>Figures and Tables</title><fig id="F1" position="float"><label>Figure 1</label><caption><p>Kaplan-Meier curve of survival from time of randomization.</p></caption><graphic xlink:href="ijmsv01p0116g01"></graphic></fig><fig id="F2" position="float"><label>Figure 2</label><caption><p>Kaplan-Meier curve of disease-free survival from time of randomization.</p></caption><graphic xlink:href="ijmsv01p0116g02"></graphic></fig><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Studies of efficacy of consolidation treatment in ovarian cancer</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="2" rowspan="1"> Study </th><th colspan="1" rowspan="1"> Year </th><th colspan="1" rowspan="1"> N. pts. </th><th colspan="1" rowspan="1"> Stage </th><th colspan="1" rowspan="1"> Treatment </th><th colspan="1" rowspan="1"> Residuum before consolidation </th><th colspan="1" rowspan="1"> Efficacy </th></tr></thead><tbody><tr><td rowspan="2" colspan="1"> 1. </td><td rowspan="2" colspan="1"> Falcone <xref ref-type="bibr" rid="B35">35</xref></td><td rowspan="2" colspan="1"> 1988 </td><td rowspan="2" colspan="1"> 16 </td><td rowspan="2" colspan="1"> IIB-IV </td><td rowspan="2" colspan="1"> WAR </td><td colspan="1" rowspan="1"> Microscopic disease (10 pts) </td><td rowspan="2" colspan="1"> Slight advantage for microscopic disease </td></tr><tr><td colspan="1" rowspan="1"> &lt; 2 cm (6 pts) </td></tr><tr><td rowspan="2" colspan="1"> 2. </td><td rowspan="2" colspan="1"> Nicoletto <xref ref-type="bibr" rid="B36">36</xref></td><td rowspan="2" colspan="1"> 1992 </td><td rowspan="2" colspan="1"> 18 </td><td rowspan="2" colspan="1"> IIIA-B </td><td rowspan="2" colspan="1"> i.p. αIFN x 4 to CCR + 4 cycles consolidation </td><td colspan="1" rowspan="1"> Microscopic disease (11 pts) </td><td rowspan="2" colspan="1"> Possibly effective in microscopic disease </td></tr><tr><td colspan="1" rowspan="1"> &lt; 2 cm (7 pts) </td></tr><tr><td rowspan="3" colspan="1"> 3. </td><td rowspan="3" colspan="1"> Menczer <xref ref-type="bibr" rid="B28">28</xref>, <xref ref-type="bibr" rid="B29">29</xref></td><td rowspan="2" colspan="1"> 1989 </td><td rowspan="2" colspan="1"> 37 </td><td rowspan="2" colspan="1"> II-IV </td><td colspan="1" rowspan="1"> i.p. cisplatin x 3 </td><td colspan="1" rowspan="1"></td><td rowspan="2" colspan="1"> i.p. cisplatin might be better than RT </td></tr><tr><td colspan="1" rowspan="1"> WAR </td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1"> 1995 </td><td colspan="1" rowspan="1"> 21 </td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"> i.p. cisplatin </td><td colspan="1" rowspan="1"> CCR 17 SL (10+; 7-) </td><td colspan="1" rowspan="1"> i.p. cisplatin+etoposide does not seem more effective than i.p. cisplatin alone </td></tr><tr><td rowspan="2" colspan="1"> 4. </td><td rowspan="2" colspan="1"> Bruzzone <xref ref-type="bibr" rid="B33">33</xref></td><td rowspan="2" colspan="1"> 1997 </td><td rowspan="2" colspan="1"> 111 </td><td rowspan="2" colspan="1"></td><td colspan="1" rowspan="1"> JM8 400 i.p. </td><td colspan="1" rowspan="1"></td><td rowspan="2" colspan="1"> αIFN does not improve D.F. or O.S. </td></tr><tr><td colspan="1" rowspan="1"> αIFN+JM8 400 i.p. </td><td colspan="1" rowspan="1"></td></tr><tr><td rowspan="2" colspan="1"> 5. </td><td rowspan="2" colspan="1"> Barakat <xref ref-type="bibr" rid="B37">37</xref></td><td rowspan="2" colspan="1"> 1998 </td><td rowspan="2" colspan="1"> 36 </td><td rowspan="2" colspan="1"> IIC-IV </td><td rowspan="2" colspan="1"> i.p. cisplatin VP 16 x 3 </td><td colspan="1" rowspan="1"> Microscopic disease (13 pts) </td><td rowspan="2" colspan="1"> i.p. cisplatin improved disease-free survival </td></tr><tr><td colspan="1" rowspan="1"> Nihil </td></tr><tr><td rowspan="2" colspan="1"> 6. </td><td rowspan="2" colspan="1"> Pickel <xref ref-type="bibr" rid="B23">23</xref></td><td rowspan="2" colspan="1"> 1999 </td><td rowspan="2" colspan="1"> 64 </td><td rowspan="2" colspan="1"></td><td colspan="1" rowspan="1"> 32 pts - WAR </td><td colspan="1" rowspan="1"></td><td rowspan="2" colspan="1"> RT offers promising results </td></tr><tr><td colspan="1" rowspan="1"> 32 pts - nihil </td><td colspan="1" rowspan="1"></td></tr></tbody></table><table-wrap-foot><fn><p>WAR= whole abdominal radiation; RT = radiotherapy; nihil = no treatment; D.F.= median disease-free survival; O.S.= median overall survival; i.p. = intraperitoneal; CCR= complete clinical remission; JM8 = Carboplatin; αIFN = interferon α; SL = second look</p></fn></table-wrap-foot></table-wrap><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>Patient characteristics</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="2" rowspan="1"> Characteristics </th><th colspan="1" rowspan="1"> Cisplatin (n=60 pts) </th><th colspan="1" rowspan="1"> Nihil (n=61 pts) </th></tr></thead><tbody><tr><td colspan="1" rowspan="1"><bold>1.</bold></td><td colspan="1" rowspan="1"><bold>Median Age (years) </bold></td><td colspan="1" rowspan="1"> 55 </td><td colspan="1" rowspan="1"> 55 </td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"> Range </td><td colspan="1" rowspan="1"> 38-76 </td><td colspan="1" rowspan="1"> 16-73 </td></tr><tr><td colspan="1" rowspan="1"><bold>2.</bold></td><td colspan="1" rowspan="1"><bold>Stage (FIGO)</bold></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"> IC </td><td colspan="1" rowspan="1"> 3 (4.9%) </td><td colspan="1" rowspan="1"> 12 (19.7%) </td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"> IIB-C </td><td colspan="1" rowspan="1"> 13 (21.3%) </td><td colspan="1" rowspan="1"> 17 (27.9%) </td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"> IIIA-B-C + IV </td><td colspan="1" rowspan="1"> 45 (73.8%) </td><td colspan="1" rowspan="1"> 32 (52.4%) </td></tr><tr><td colspan="1" rowspan="1"><bold>3.</bold></td><td colspan="1" rowspan="1"><bold>Histological Type</bold></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"> Serous Papillary </td><td colspan="1" rowspan="1"> 45 (73.8%) </td><td colspan="1" rowspan="1"> 32 (52.5%) </td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"> Undifferentiated </td><td colspan="1" rowspan="1"> 3 (4.9%) </td><td colspan="1" rowspan="1"> 6 (9.8%) </td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"> Clear Cell </td><td colspan="1" rowspan="1"> 2 (3.3%) </td><td colspan="1" rowspan="1"> 2 (3.3%) </td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"> Endometrioid </td><td colspan="1" rowspan="1"> 8 (13.1%) </td><td colspan="1" rowspan="1"> 15 (24.6%) </td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"> Mucinous </td><td colspan="1" rowspan="1"> - </td><td colspan="1" rowspan="1"> 4 (6.6%) </td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"> Mixed </td><td colspan="1" rowspan="1"> 3 (4.9%) </td><td colspan="1" rowspan="1"> 2 (3.3%) </td></tr><tr><td colspan="1" rowspan="1"><bold>4.</bold></td><td colspan="1" rowspan="1"><bold>Histological Grade</bold></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"> 1-2 </td><td colspan="1" rowspan="1"> 30 (49.2%) </td><td colspan="1" rowspan="1"> 34 (55.7%) </td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"> 3 </td><td colspan="1" rowspan="1"> 31 (50.8%) </td><td colspan="1" rowspan="1"> 27 (44.3%) </td></tr><tr><td colspan="1" rowspan="1"><bold>5.</bold></td><td colspan="1" rowspan="1"><bold>Type of first line chemotherapy</bold></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"> Anthracyclin-Cyclophosphamide </td><td colspan="1" rowspan="1"> 30 (49.2%) </td><td colspan="1" rowspan="1"> 24 (39.3%) </td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"> Mitoxantrone-Cisplatin </td><td colspan="1" rowspan="1"> 2 (3.3%) </td><td colspan="1" rowspan="1"> 3 (4.9%) </td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"> Cyclophosphamide-Cisplatin </td><td colspan="1" rowspan="1"> 29 (47.5%) </td><td colspan="1" rowspan="1"> 34 (55.7%) </td></tr><tr><td colspan="1" rowspan="1"><bold>6.</bold></td><td colspan="1" rowspan="1"><bold>Type of Surgery</bold></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"> Laparoscopy </td><td colspan="1" rowspan="1"><bold>-</bold></td><td colspan="1" rowspan="1"> 1 (1.6%) </td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"> Tumor Reduction </td><td colspan="1" rowspan="1"> 13 (21.3%) </td><td colspan="1" rowspan="1"> 5 (8.2%) </td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"> Radical Surgery </td><td colspan="1" rowspan="1"> 48 (78.7%) </td><td colspan="1" rowspan="1"> 55 (90.2%) </td></tr><tr><td colspan="1" rowspan="1"><bold>7.</bold></td><td colspan="1" rowspan="1"><bold>Postsurgical</bold><bold> Residual Disease (first look)</bold></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"> Residuum ≤2 cm </td><td colspan="1" rowspan="1"> 51 (83.6%) </td><td colspan="1" rowspan="1"> 55 (90.2%) </td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"> Residuum &gt;2 cm </td><td colspan="1" rowspan="1"> 10 (16.4%) </td><td colspan="1" rowspan="1"> 6 (9.8%) </td></tr><tr><td colspan="1" rowspan="1"><bold>8.</bold></td><td colspan="1" rowspan="1"> Total number of cycles completed </td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"> 0 </td><td colspan="1" rowspan="1"> 1 (%) </td><td colspan="1" rowspan="1"><bold>-</bold></td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"> 1 </td><td colspan="1" rowspan="1"> 4 (%) </td><td colspan="1" rowspan="1"><bold>-</bold></td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"> 2 </td><td colspan="1" rowspan="1"> 9 (%) </td><td colspan="1" rowspan="1"><bold>-</bold></td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"> 3 </td><td colspan="1" rowspan="1"> 44 (%) </td><td colspan="1" rowspan="1"><bold>-</bold></td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"> 4 </td><td colspan="1" rowspan="1"> 2 (%) </td><td colspan="1" rowspan="1"><bold>-</bold></td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"> 5 </td><td colspan="1" rowspan="1"><bold>-</bold></td><td colspan="1" rowspan="1"><bold>-</bold></td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"> 6 </td><td colspan="1" rowspan="1"> 1 (%) </td><td colspan="1" rowspan="1"><bold>-</bold></td></tr></tbody></table></table-wrap><table-wrap id="T3" position="float"><label>Table 3</label><caption><p>Toxicity in patients who received Cisplatin consolidation therapy</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="2" rowspan="1"> Toxicity </th><th colspan="1" rowspan="1"> Grade 1 </th><th colspan="1" rowspan="1"> Grade 2 </th><th colspan="1" rowspan="1"> Grade 3 </th><th colspan="1" rowspan="1"> Grade 4 </th><th colspan="1" rowspan="1"> Total </th></tr></thead><tbody><tr><td colspan="1" rowspan="1"> 1. </td><td colspan="1" rowspan="1"> Allergic reaction </td><td colspan="1" rowspan="1"> - </td><td colspan="1" rowspan="1"> - </td><td colspan="1" rowspan="1"> 1 (1.6%) </td><td colspan="1" rowspan="1"> - </td><td colspan="1" rowspan="1"> 1 (1.6%) </td></tr><tr><td colspan="1" rowspan="1"> 2. </td><td colspan="1" rowspan="1"> Alopecia </td><td colspan="1" rowspan="1"> - </td><td colspan="1" rowspan="1"> 4 (6.6%) </td><td colspan="1" rowspan="1"> 1 (1.6%) </td><td colspan="1" rowspan="1"> - </td><td colspan="1" rowspan="1"> 5 (8.2%) </td></tr><tr><td colspan="1" rowspan="1"> 3. </td><td colspan="1" rowspan="1"> Hematologic </td><td colspan="1" rowspan="1"> 4 (6.6%) </td><td colspan="1" rowspan="1"> 11 (18.0%) </td><td colspan="1" rowspan="1"> 4 (6.6%) </td><td colspan="1" rowspan="1"> - </td><td colspan="1" rowspan="1"> 19 (31.1%) </td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"> - Anemia </td><td colspan="1" rowspan="1"> 2 (3.3%) </td><td colspan="1" rowspan="1"> - </td><td colspan="1" rowspan="1"> - </td><td colspan="1" rowspan="1"> - </td><td colspan="1" rowspan="1"> 2 (3.3%) </td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"> - Leukopenia </td><td colspan="1" rowspan="1"> 3 (4.9%) </td><td colspan="1" rowspan="1"> 10 (16.4%) </td><td colspan="1" rowspan="1"> - </td><td colspan="1" rowspan="1"> - </td><td colspan="1" rowspan="1"> 13 (21.3%) </td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"> - Neutropenia </td><td colspan="1" rowspan="1"> 2 (3.3%) </td><td colspan="1" rowspan="1"> - </td><td colspan="1" rowspan="1"> 1 (1.6%) </td><td colspan="1" rowspan="1"> - </td><td colspan="1" rowspan="1"> 3 (4.9%) </td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"> - Thrombocytopenia </td><td colspan="1" rowspan="1"> 1 (1.6%) </td><td colspan="1" rowspan="1"> 1 (1.6%) </td><td colspan="1" rowspan="1"> - </td><td colspan="1" rowspan="1"> 1 (1.6%) </td><td colspan="1" rowspan="1"> 3 (4.9%) </td></tr><tr><td colspan="1" rowspan="1"> 4. </td><td colspan="1" rowspan="1"> Infection </td><td colspan="1" rowspan="1"> 2 (3.3%) </td><td colspan="1" rowspan="1"> - </td><td colspan="1" rowspan="1"> 1 (1.6%) </td><td colspan="1" rowspan="1"> - </td><td colspan="1" rowspan="1"> 3 (4.9%) </td></tr><tr><td colspan="1" rowspan="1"> 5. </td><td colspan="1" rowspan="1"> Mucositis </td><td colspan="1" rowspan="1"> 3 (4.9%) </td><td colspan="1" rowspan="1"> 3 (4.9%) </td><td colspan="1" rowspan="1"> - </td><td colspan="1" rowspan="1"> 1 (1.6%) </td><td colspan="1" rowspan="1"> 7 (11.5%) </td></tr><tr><td colspan="1" rowspan="1"> 6. </td><td colspan="1" rowspan="1"> Nausea-Vomiting </td><td colspan="1" rowspan="1"> 1 (1.6%) </td><td colspan="1" rowspan="1"> 10 (16.4%) </td><td colspan="1" rowspan="1"> 17 (27.9%) </td><td colspan="1" rowspan="1"> 10 (16.4%) </td><td colspan="1" rowspan="1"> 38 (62.3%) </td></tr><tr><td colspan="1" rowspan="1"> 7. </td><td colspan="1" rowspan="1"> Renal </td><td colspan="1" rowspan="1"> 4 (6.6%) </td><td colspan="1" rowspan="1"> - </td><td colspan="1" rowspan="1"> - </td><td colspan="1" rowspan="1"> - </td><td colspan="1" rowspan="1"> 4 (6.6%) </td></tr></tbody></table></table-wrap><table-wrap id="T4" position="float"><label>Table 4</label><caption><p>Relapses: isolated or multiple relapses divided by site.</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="2" rowspan="1"> Site of relapse </th><th colspan="1" rowspan="1"> Cisplatin (n=61 pts) </th><th colspan="1" rowspan="1"> Nihil (n=61pts) </th></tr></thead><tbody><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"> Total </td><td colspan="1" rowspan="1"> 36 (59.0%) </td><td colspan="1" rowspan="1"> 30 (49.2%) </td></tr><tr><td colspan="1" rowspan="1"> 1. </td><td colspan="1" rowspan="1"> Peritoneum </td><td colspan="1" rowspan="1"> 15 (24.6%) </td><td colspan="1" rowspan="1"> 10 (16.4%) </td></tr><tr><td colspan="1" rowspan="1"> 2. </td><td colspan="1" rowspan="1"> Retroperitoneum </td><td colspan="1" rowspan="1"> 3 (4.9%) </td><td colspan="1" rowspan="1"> 2 (3.3%) </td></tr><tr><td colspan="1" rowspan="1"> 3. </td><td colspan="1" rowspan="1"> Pelvis </td><td colspan="1" rowspan="1"> 5 (8.2%) </td><td colspan="1" rowspan="1"> 11 (18%) </td></tr><tr><td colspan="1" rowspan="1"> 4. </td><td colspan="1" rowspan="1"> Lumbo-aortic LN </td><td colspan="1" rowspan="1"> 6 (9.8%) </td><td colspan="1" rowspan="1"> 3 (4.9%) </td></tr><tr><td colspan="1" rowspan="1"> 5. </td><td colspan="1" rowspan="1"> Inguinal LN </td><td colspan="1" rowspan="1"> 5 (8.2%) </td><td colspan="1" rowspan="1"> 1 (1.6%) </td></tr><tr><td colspan="1" rowspan="1"> 6. </td><td colspan="1" rowspan="1"> Supraclavear LN </td><td colspan="1" rowspan="1"> 2 (3.3%) </td><td colspan="1" rowspan="1"> 1 (1.6%) </td></tr><tr><td colspan="1" rowspan="1"> 7. </td><td colspan="1" rowspan="1"> Vaginal dome </td><td colspan="1" rowspan="1"> 1 (1.6%) </td><td colspan="1" rowspan="1"> 5 (8.2%) </td></tr><tr><td colspan="1" rowspan="1"> 8. </td><td colspan="1" rowspan="1"> Spleen </td><td colspan="1" rowspan="1"> 1 (1.6%) </td><td colspan="1" rowspan="1"> 2 (3.3%) </td></tr><tr><td colspan="1" rowspan="1"> 9. </td><td colspan="1" rowspan="1"> Lung-pleura </td><td colspan="1" rowspan="1"> 5 (8.2%) </td><td colspan="1" rowspan="1"> 6 (9.8%) </td></tr><tr><td colspan="1" rowspan="1"> 10. </td><td colspan="1" rowspan="1"> Liver </td><td colspan="1" rowspan="1"> 3 (4.9%) </td><td colspan="1" rowspan="1"> 4 (6.6%) </td></tr><tr><td colspan="1" rowspan="1"> 11. </td><td colspan="1" rowspan="1"> CA 125 </td><td colspan="1" rowspan="1"> 5 (8.2%) </td><td colspan="1" rowspan="1"> 1 (1.6%) </td></tr><tr><td colspan="1" rowspan="1"> 12. </td><td colspan="1" rowspan="1"> Bone </td><td colspan="1" rowspan="1"> 1 (1.6%) </td><td colspan="1" rowspan="1"> 1 (1.6%) </td></tr><tr><td colspan="1" rowspan="1"> 13. </td><td colspan="1" rowspan="1"> Rectum-sigma </td><td colspan="1" rowspan="1"> 1 (1.6%) </td><td colspan="1" rowspan="1"> 1 (1.6%) </td></tr><tr><td colspan="1" rowspan="1"> 14. </td><td colspan="1" rowspan="1"> Ileo-paraintestinal </td><td colspan="1" rowspan="1"> 1 (1.6%) </td><td colspan="1" rowspan="1"> 3 (4.9%) </td></tr><tr><td colspan="1" rowspan="1"> 15. </td><td colspan="1" rowspan="1"> Peritoneum + Pelvis+ Vaginal dome + Rectum-sigma + Ileo-paraintestinal </td><td colspan="1" rowspan="1"> 23 (37.7%) </td><td colspan="1" rowspan="1"> 30 (49.2%) </td></tr><tr><td colspan="1" rowspan="1"> 16. </td><td colspan="1" rowspan="1"> Retroperitoneum + Lumbo-aortic LN + Inguinal LN + Supraclavear LN </td><td colspan="1" rowspan="1"> 16 (26.2%) </td><td colspan="1" rowspan="1"> 7 (11.5%) </td></tr></tbody></table><table-wrap-foot><fn><p>LN = lymph node</p></fn></table-wrap-foot></table-wrap></sec></back></article>